The [complement system](/entities/complement-system) is a critical component of the innate immune system that plays a dual role in neurodegeneration - both in protective immune surveillance and in driving pathological neuroinflammation. Therapeutic targeting of complement proteins represents a growing area of interest for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders["@complement2022"].
The complement system has emerged as a key link between neuroinflammation and protein aggregation in neurodegenerative diseases. While complement proteins play essential roles in synaptic pruning during development and immune defense, dysregulated complement activation can drive pathology through microglial activation, synapse loss, and chronic neuroinflammation.
Investment Context
The complement therapeutics space has seen significant investment following:
Success in other indications: C5 inhibitors (eculizumab, ravulizumab) are approved for rare diseases
Alzheimer's genetics: [TREM2](/proteins/trem2) variants highlight microglial pathways linked to complement
Anti-CD20 de-risking: Similar immune modulation approach validated in MS
Key challenges remain:
[BBB](/entities/blood-brain-barrier) penetration: Most complement inhibitors are large biologics
Infection risk: Complement inhibition increases susceptibility to infections
Timing: Optimal patient selection (early vs. late disease) unclear
C1q blockade: Early but promising; no CNS clinical trials yet
Oral small molecules: Limited options for chronic dosing
Brain-penetrant agents: Critical gap for complement inhibition
Combination approaches: Complement + other mechanisms (TREM2, tau)
Biomarkers: Need for complement activation markers in CSF/blood
Opportunities
Genetic validation from AD genetics (C1QA, C1QB variants)
Link to TREM2 pathway provides biological rationale
Synaptic protection as potential disease-modifying mechanism
Conclusion
Complement therapeutics represent a promising but challenging area in neurodegeneration R&D. While the biological rationale is strong, BBB penetration and infection risk remain key hurdles. The field awaits late-stage clinical data to validate this approach.